Photo by nci from unsplash
Sign Up to like & get
recommendations!
2
Published in 2017 at "Blood Cancer Journal"
DOI: 10.1038/bcj.2017.76
Abstract: The recent remarkable advances in multiple myeloma (MM) therapy and outcomes have had mixed impact on patients with adverse risk genetics, many of whom continue to have inferior outcomes. This applies particularly to deletion of…
read more here.
Keywords:
del 17p;
timing tp53;
prevalence timing;
tp53 mutations ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "International Journal of Laboratory Hematology"
DOI: 10.1111/ijlh.14248
Abstract: Detection of del(17p) in myeloma is generally performed by fluorescence in situ hybridization (FISH) on a slide with analysis of up to 200 nuclei. The small cell sample analyzed makes this a low precision test.…
read more here.
Keywords:
detection del;
17p bone;
del 17p;
bone marrow ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-110948
Abstract: Introduction Chronic Lymphocytic Leukaemia (CLL) is the most prevalent leukaemia in the Western world and characterised by clinical heterogeneity. IgHV mutation status, mutations in the TP53 gene and deletions of the p-arm of chromosome 17…
read more here.
Keywords:
sample;
cll;
detection;
del 17p ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-115458
Abstract: Introduction Del(17p) detected by fluorescence in situ hybridisation (FISH) of bone marrow plasma cells (BMPCs) is an adverse prognostic factor in patients with multiple myeloma (MM). While the natural history and prognostic factors in patients…
read more here.
Keywords:
del 17p;
research;
membership entity;
research funding ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136242
Abstract: Introduction: Increased understanding of the pathophysiology of multiple myeloma (MM) and the introduction of new drugs has led to considerable survival improvements in recent years. The International Myeloma Working Group consensus recently updated the definition…
read more here.
Keywords:
high risk;
del 17p;
research funding;
Sign Up to like & get
recommendations!
0
Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3908
Abstract: Background: Chronic lymphocytic leukemia (CLL) exhibits diverse clinical manifestations, and access to diagnostic and staging tools varies significantly throughout Latin America (LATAM). To improve our understanding of how the disease presents and how it is…
read more here.
Keywords:
stage stage;
registry;
stage;
chronic lymphocytic ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-4583
Abstract: Introduction Approximately 10% of patients with newly diagnosed multiple myeloma (MM) have the FISH cytogenetic abnormality, Del 17p, of whom one fifth also have t(4;14) or t(14;16), these additional translocations being associated with worse survival…
read more here.
Keywords:
tandem asct;
tandem;
transplant;
high risk ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.3116.3116
Abstract: Introduction: Multiple myeloma (MM) is known as heterogeneous disease characterized by the clonal proliferation of tumor plasma cells. Recently, the prognosis of MM is classified depending on the appearance of cytogenetic abnormalities. However, no publication…
read more here.
Keywords:
del 17p;
17p del;
prognosis;
del 13q ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0509-0
Abstract: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with…
read more here.
Keywords:
rituximab;
del 17p;
lymphocytic leukemia;
chronic lymphocytic ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2022.40.16_suppl.8062
Abstract: 8062 Background: Translocation (4;14) is a known adverse prognostic factor in myeloma. However, utilization of proteasome inhibitors (PIs) in myeloma has abrogated the negative impact of t(4;14) in myeloma, and some investigators question whether t(4;14)…
read more here.
Keywords:
long term;
maintenance;
del 17p;
impact ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.18722
Abstract: We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma (NDMM/RRMM) patients with del(17p). Thirteen prospective studies that evaluated 3,187 MM patients, including 685with del(17p), were included in our meta-analysis. The incidence of del(17p)…
read more here.
Keywords:
del 17p;
newly diagnosed;
rrmm patients;
dexamethasone ... See more keywords